Skip to main content
. Author manuscript; available in PMC: 2015 Sep 24.
Published in final edited form as: Clin Immunol. 2011 Feb 26;139(3):302–313. doi: 10.1016/j.clim.2011.02.014

Figure 2.

Figure 2

Expansion of IFNγ+ T-cells with short-term in vitro expansion by Elispot. PBMC were stimulated with 1 mg/ml survivin or glypican-3 5mer peptide pools for 8 days with rhIL-2 100U/ml added on days 2 and 5. T-cell lines were re-stimulated with peptide pools in Elispot assays. Background was subtracted and results normalized to SFU per 106 PBMC. Comparison of ex vivo and in vitro 15mer peptide responses for non-cirrhotic patients (A), cirrhotic patients (B), and hepatocellular carcinoma patients (C). P-values were obtained by matched pair analyses. (D). Comparison of serum glypican-3 levels in patients with and without IFNγ+ glypican-3-specific T-cells greater than 500 SFU/106 PBMC after expansion.